MedTrace Logo

Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention

NCT06111885 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2026-05-06

No results posted yet for this study

Summary

The aim of this study is to test the efficacy of the two long-acting thiazide-like diuretics indapamide and chlorthalidone in reducing urine supersaturation for calcium oxalate and calcium phosphate compared to the short-acting thiazide diuretic hydrochlorothiazide for the prevention of calcium-containing kidney stones.

Conditions

  • Kidney Stone

Interventions

DRUG

Indapamide 2.5 MG

1 indapamide 2.5 mg capsule per day for 28 days

DRUG

Hydrochlorothiazide 50Mg

1 hydrochlorothiazide 50 mg capsule per day for 28 days

DRUG

Chlorthalidone 25mg

1 chlorthalidone 25 mg capsule per day for 28 days

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Daniel G Fuster, M.D. · Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, Bern Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06111885 on ClinicalTrials.gov